BORTEZOMIB
Bortezomib is a proteasome inhibitor used in multiple myeloma and mantle cell lymphoma. It disrupts protein degradation, triggering cancercell apoptosis. Benefits include strong antitumor efficacy. Side effects include neuropathy, thrombocytopenia, fatigue, and gastrointestinal symptoms. Only GMP materials will be supplied, logistics all according to GDP.
About MedicaPharma
MedicaPharma distributes high-quality active pharmaceutical ingredients (APIs) to hospitals, commercial (compounding) pharmacies, research institutes, and universities worldwide.
Network of over +400 GMP API producers
Let us handle your sourcing / supply activities. Highly experienced in sourcing specialty raw pharmaceutical ingredients from niche GMP manufacturers around the world.
Why Choose MedicaPharma
Niche API specialist - Pro-active supply partner - High service level - Global network - Logistics according to GDP regulations
Product Description
Mechanism of action
Bortezomib is a reversible inhibitor of the 26S proteasome, specifically targeting the chymotrypsinlike activity of the 5 subunit. Inhibiting proteasomal degradation leads to accumulation of ubiquitinated proteins, disruption of NF-κB activation, ERstress induction, mitochondrial apoptosis and inhibition of tumourcell proliferation.
Benefits and advantages
Used in multiple myeloma research, proteasomeinhibition studies, apoptosispathway modelling, ubiquitinproteasome system analysis, ERstress signalling research and drugresistance investigation.
Side effects and risks
Risks include peripheral neuropathy, thrombocytopenia, neutropenia, cardiac dysfunction, hepatic injury and GI toxicity. Handle with full cytotoxicagent containment and PPE.
Only GMP materials will be supplied, logistics all according to GDP.
Datasheet
| Molecular Formula | C19H25BN4O4 |
|---|---|
| Molecular Weight | 384.2 g/mol |
| CAS Number | 179324-69-7 |
| Storage Condition | Unopened vials may be stored at controlled room temperature 25 °C (77 °F); excursions permitted from 15 to 30 °C (59 to 86 °F). Retain in original package to protect from light. |
| Solubility | The solubility of bortezomib, as the monomeric boronic acid, is 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5. |
| Purity | Purity information is available upon request (COA). |
| Synonym | Bortezomib; 179324-69-7; Velcade; PS-341; LDP-341 |
| IUPAC/Chemical Name | [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid |
| InChl Key | GXJABQQUPOEUTA-RDJZCZTQSA-N |
| InChl Code | InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1 |
| References |
3D Conformer.
(Click, turn or enlarge)
Download our GMP API Product List.
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.
